Universal Ibogaine (TSX.V: IBO) (“UI”), a life sciences company with a mission to transform the addiction treatment industry with medicalized ibogaine-centered care, today provided a year-end summary of 2022 accomplishments. “2022 was a busy year of behind-the-scenes activity laying the foundations with Health Canada in preparation for the planned clinical trial application and sourcing the related ibogaine drug supply,” said Nick Karos, chief executive officer and board member of Universal Ibogaine. “We are finalizing discussions with several potential funding partners and intend on closing the second round of our current convertible debt financing very shortly. 2023 will be a pivotal year for our company, for our shareholders and for Canadians who are actively seeking ibogaine treatment.”
To view the full press release, visit https://ibn.fm/dvjpV
About Universal Ibogaine Inc. (“UI”)
UI is a life sciences company with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder, and ultimately to utilize that protocol globally through planned future licensing agreements. UI is concurrently developing a state-of-the-art holistic addiction treatment protocol at its Kelburn Recovery Centre that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction. For more information about the company, visit https://universalibogaine.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork